Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 3/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10174688 | 0.77 | CDK4 (0.39) | CCR6 | |
| SCHEMBL10309780 | 0.76 | CCR6 (0.36) | NOTUMCCR6CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL10309756 | 0.72 | GRM2 (0.39) | MAP3K5NOTUM | |
| SCHEMBL13436507 | 0.71 | CCR6 (0.51) | MKNK1MKNK2CCR6CHRNB2CHRNA4 | |
| SCHEMBL25855696 | 0.69 | CCR6 (0.55) | NOTUMCCR6CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL20457911 | 0.67 | ALDH1A1 (0.48) | MAP3K5NOTUM | |
| SCHEMBL17660602 | 0.67 | ALDH1A1 (0.48) | MAP3K5NOTUM | |
| SCHEMBL17660616 | 0.67 | ALDH1A1 (0.48) | MAP3K5NOTUM | |
| SCHEMBL17660608 | 0.67 | ALDH1A1 (0.48) | MAP3K5NOTUM | |
| SCHEMBL20457975 | 0.67 | ALDH1A1 (0.48) | MAP3K5NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | MKNK1 3969/4885MKNK2 4205/4885MAP3K5 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.